The short answer: Yes, for most healthy adults over 65, the evidence says GLP-1 drugs work about as well as they do in younger adults. The FDA labels for Wegovy, Zepbound, Ozempic, and Mounjaro report no overall difference in effectiveness after 65. The main caveat is in people 75 and older: in the SELECT heart trial, they had more hip and pelvis fractures on Wegovy than on placebo. Dehydration, muscle loss, and low appetite also deserve closer watch with age.
Do GLP-1 drugs work as well after 65?
The best data come from age-split analyses of the large trials. They show similar weight loss and similar benefits in older and younger adults.
- Tirzepatide (Zepbound, Mounjaro). A 2026 post hoc analysis pooled the SURMOUNT-1 to -5, SURMOUNT-OSA, and SUMMIT trials. It found "clinically meaningful weight reduction" in adults 65 and older, "broadly comparable" to results under 65. Risk factors and quality of life also improved (Alfaris et al., Diabetes, Obesity and Metabolism, 2026). Eli Lilly, the maker, funded the analysis and employed most of the authors.
- Semaglutide (Wegovy) in heart failure. The STEP-HFpEF trials enrolled 1,145 people with obesity-related heart failure with preserved ejection fraction. Of these, 42.4% were 65 to 74 and 25.5% were 75 or older. Benefits on symptoms and body weight were consistent across every age group, and so was safety (Pandey et al., European Journal of Heart Failure, 2025).
- SELECT heart outcomes. The Wegovy label says SELECT enrolled 17,604 adults with heart disease and overweight or obesity. Ages ran from 45 to 93, with a mean of 62. The label says effectiveness did not differ overall between people 65 and older and younger adults.
One gap stands out. Most weight-loss trials enrolled few people over 75. So the data for the oldest adults are thinner than for people in their late 60s.
What do the FDA labels say about older adults?
Every FDA label has a section called "Geriatric Use" (section 8.5). Here is what each one reports.
- Wegovy. In the weight trials, 233 (9%) treated patients were 65 to under 75, and 23 (1%) were 75 or older. In the heart outcomes trial, 2,656 (30%) were 65 to 75, and 703 (8%) were 75 or older. The label reports "no overall difference in the effectiveness" after 65. It adds that people 75 and older had more serious adverse reactions overall, on both Wegovy and placebo.
- Zepbound. In two weight studies, 226 (9%) treated patients were 65 or older and 13 (0.5%) were 75 or older. The label reports no overall differences in safety or effectiveness. It says the sleep apnea studies had too few patients over 65 to judge.
- Ozempic. In the diabetes trials, 744 (23.6%) treated patients were 65 or older and 102 (3.2%) were 75 or older. In SUSTAIN 6, 788 (48%) were 65 or older. The label finds no overall differences, but says "greater sensitivity of some older individuals cannot be ruled out."
- Mounjaro. In seven pooled trials, 1,539 (30.1%) treated patients were 65 or older and 212 (4.1%) were 75 or older. In its heart outcomes trial, 3,327 (50%) were 65 or older. The label reports no overall differences in safety or effectiveness.
None of these labels sets a different starting dose for older adults. None lists age as a reason not to use the drug.
Is there a fracture signal in people over 75?
Yes, and it is the clearest age-specific warning on any of these labels. The Wegovy label reports more hip and pelvis fractures on Wegovy than on placebo in SELECT in two groups:
- Patients 75 and older: 2.4% (17 of 703) on Wegovy versus 0.6% (4 of 663) on placebo.
- Female patients: 1% (24 of 2,448) versus 0.2% (5 of 2,424).
The absolute numbers are small, but a hip fracture at 80 is a serious event. The cause is not settled. Faster weight loss, less padding over the hip, and loss of lean mass are all possible factors.
Other data point the other way. The tirzepatide analysis found no meaningful difference in falls or fractures between drug and placebo in adults 65 and older (Alfaris et al.). A 2026 study of more than 40,000 matched adults 65 and older with type 2 diabetes compared these drugs with DPP-4 inhibitors. It linked semaglutide and tirzepatide to fewer falls and fewer femoral fractures after one year (Chen et al., Osteoporosis International, 2026). That was an observational study, so it cannot prove cause.
Why do dehydration and kidney injury matter more with age?
Nausea, vomiting, and diarrhea are the most common side effects of GLP-1 drugs. In older adults, fluid losses can cause problems faster. Thirst often weakens with age, and many older adults take diuretics or blood pressure drugs.
The Wegovy label warns of acute kidney injury "in some cases requiring hemodialysis." Most reported cases came after GI side effects that led to dehydration. The label says kidney problems were more common in people with existing kidney disease and during dose increases. It tells patients to avoid fluid loss and to report persistent nausea, vomiting, or diarrhea.
The Zepbound and Mounjaro labels give the same advice: monitor kidney function if GI side effects could cause volume depletion. The Ozempic, Zepbound, and Mounjaro labels recommend no dose change for kidney disease alone.
Low blood sugar is a second concern. The labels warn that combining these drugs with insulin or a sulfonylurea raises the risk of hypoglycemia. Many older adults with type 2 diabetes take one of those drugs.
What about muscle, appetite, and falls?
Some of the weight lost on any GLP-1 drug is lean mass. Our guide to GLP-1 drugs and muscle loss covers the trial scans in detail. The share of lean mass lost looks similar to other kinds of weight loss. But older adults start with less muscle, so the same loss can matter more for strength and balance.
Appetite is the other issue. These drugs reduce hunger, which is the point. In an older adult who already eats little, that can mean too little protein and too few calories. Frailty, recent unplanned weight loss, and a small appetite are reasons for a careful talk before starting.
Dizziness from dehydration, weakness from muscle loss, and low blood sugar can each raise fall risk. Strength training and enough protein are the two steps with the most evidence for protecting muscle. The sister site calories.md covers daily energy and protein needs.
What should older adults ask their clinician?
Bring a full list of your medicines and conditions. These questions cover the age-specific issues:
- Is my weight a real health risk, or am I at risk of frailty or undernutrition?
- Do I have a history of osteoporosis, fractures, or falls? Should I have a bone density scan first?
- How will we watch my kidney function, especially during dose increases?
- Do any of my diabetes drugs need to change to prevent low blood sugar?
- How much protein should I eat, and can I start a strength program?
- What should I do if I cannot keep fluids down?
Some people should not take these drugs at any age, such as people with a personal or family history of medullary thyroid cancer. See who should not take a GLP-1 drug for the full list. For semaglutide product details, see ozempic.md.
The bottom line
Age alone does not rule out a GLP-1 drug. The FDA labels and the age-split trial analyses show similar benefits after 65, including heart benefits in SELECT. The extra risks cluster in people 75 and older and in people who are frail, dehydrated, or eating very little. The most specific warning is the higher rate of hip and pelvis fractures with Wegovy in SELECT patients 75 and older. A clinician who knows your bones, kidneys, and medicines can weigh these risks for you.
Last updated: October 2026. This article is for informational purposes only and does not constitute medical advice. Talk with your doctor before starting, stopping, or changing any medication, especially if you are over 65.